tradingkey.logo

Neuraxis Inc

NRXS
2.540USD
0.000
Close 11/05, 16:00ETQuotes delayed by 15 min
25.04MMarket Cap
LossP/E TTM

Neuraxis Inc

2.540
0.000
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Neuraxis Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neuraxis Inc's Score

Industry at a Glance

Industry Ranking
113 / 210
Overall Ranking
253 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Neuraxis Inc Highlights

StrengthsRisks
Neuraxis, Inc. is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It is engaged in advancing science with its IB-Stim therapy, based on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which was developed internally by the Company. The Company's first product, IB-Stim, is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The IB-Stim is intended to be used for 120 hours per week for three consecutive weeks, and not to exceed four weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS. Other indications in its pipeline are comprised of functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.69M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.69M.
Undervalued
The company’s latest PE is -2.43, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.53M shares, increasing 16.73% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 6.53, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 894.09K, representing a year-over-year increase of 46.21%, while its net profit experienced a year-over-year increase of 34.95%.

Score

Industry at a Glance

Previous score
6.53
Change
0

Financials

8.79

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.54

Operational Efficiency

2.57

Growth Potential

6.64

Shareholder Returns

7.11

Neuraxis Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.60, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.43, which is -100.00% below the recent high of 0.00 and -246.82% above the recent low of -8.41.

Score

Industry at a Glance

Previous score
7.60
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 113/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Buy
Current Rating
0.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Neuraxis Inc
NRXS
2
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.38, which is lower than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 3.49 and the support level at 2.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.40
Change
-0.02

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.243
Neutral
RSI(14)
35.883
Neutral
STOCH(KDJ)(9,3,3)
2.239
Oversold
ATR(14)
0.327
High Vlolatility
CCI(14)
-98.850
Neutral
Williams %R
98.611
Oversold
TRIX(12,20)
-0.085
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
2.654
Sell
MA10
2.973
Sell
MA20
3.126
Sell
MA50
2.868
Sell
MA100
2.693
Sell
MA200
2.516
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Hannasch (Brian)
1.13M
+61.42%
Brown (Christopher Robin)
792.84K
--
AIGH Capital Management, LLC.
297.44K
+1397.01%
Apis Capital Advisors LLC
124.02K
--
Parsons Capital Management, Inc.
116.73K
--
Worth Venture Partners, LLC
102.56K
--
Manatuck Hill Partners, LLC
50.42K
--
The Vanguard Group, Inc.
Star Investors
27.98K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 3.37, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.37
Change
0
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+50.77%
240-Day Volatility
+159.32%

Return

Best Daily Return
60 days
+21.45%
120 days
+75.77%
5 years
--
Worst Daily Return
60 days
-10.89%
120 days
-19.80%
5 years
--
Sharpe Ratio
60 days
+0.60
120 days
+0.69
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+50.77%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.43
3 years
--
5 years
--
Skewness
240 days
+5.48
3 years
--
5 years
--

Volatility

Realised Volatility
240 days
+159.32%
5 years
--
Standardised True Range
240 days
+9.86%
5 years
--
Downside Risk-Adjusted Return
120 days
+182.26%
240 days
+182.26%
Maximum Daily Upside Volatility
60 days
+66.08%
Maximum Daily Downside Volatility
60 days
+53.02%

Liquidity

Average Turnover Rate
60 days
+1.28%
120 days
+14.81%
5 years
--
Turnover Deviation
20 days
-100.00%
60 days
-100.00%
120 days
-100.00%

Peer Comparison

Healthcare Equipment & Supplies
Neuraxis Inc
Neuraxis Inc
NRXS
6.29 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc
ZBH
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI